MET D1010Y

CI-VAR-00000396Explore in graph →NP_000236.2:p.Asp1010TyrNM_000245.4:c.3028G>TCIViC 1649

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
MET D1010Y	Crizotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4778 In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing… (full text at CIViC) PMID 27343443 · Schrock et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.